Richard Gregg, M.D.
Chief Scientific Officer
Dr. Gregg spent 19 years leading various groups at Bristol-Myers Squibb Research and Development before deciding to join Vitae Pharmaceuticals. Most recently, he was Vice President of Clinical Discovery, responsible for Early Clinical Development, Clinical Pharmacology, Translational Medicine and Biomarker Technologies. Dr. Gregg developed and led the Bristol’s efforts in the application of cutting edge science and analytical technologies to the clinical investigation of new drugs. He also served as Vice President of Metabolic and Cardiovascular Drug Discovery, focusing on the discovery of new drugs for diabetes, dyslipidemia, and atherosclerotic vascular disease. Before coming to Bristol, Dr. Gregg spent 10 years at the National Heart, Lung and Blood Institute, where he studied disorders of lipid and lipoprotein metabolism. He has more than 120 publications in leading medical and research journals, and has presented his research findings at national and international meetings. Dr. Gregg earned his B.S. and M.S. from Iowa State University and his M.D. from Stanford University School of Medicine. He did his internship and residency in Internal Medicine at Strong Memorial Hospital in Rochester, New York, and completed his fellowship in Endocrinology and Metabolism at the National Institutes of Health.